sleep disorders

News

Eli Lilly makes $7.8bn takeover play for Centessa

Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.

News

Eisai joins with Pokémon for sleep awareness drive

Eisai has launched a campaign to raise awareness of sleep disorders in Japan, via a partnership with smartphone app Pokémon Sleep.

News

FDA turns down Hetlioz for jet lag once again

Vanda will continue to push for approval of Hetlioz for jet lag, despite the FDA saying its trial designs were not satisfactory.

News

Graphic of man flying a white flag against a teal background

Lundbeck bows out of bidding war for Avadel

Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.

News

Lundbeck makes bid for Avadel, trying to displace Alkermes

Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

News

Alkermes breaks new ground in narcolepsy with orexin drug

Alkermes' alixorexton is the first orexin 2 receptor agonist to show efficacy in phase 2 trials involving patients with both main narcolepsy subtypes.

Eli Lilly makes $7.8bn takeover play for Centessa

Eisai joins with Pokémon for sleep awareness drive

FDA turns down Hetlioz for jet lag once again

Lundbeck bows out of bidding war for Avadel

Lundbeck makes bid for Avadel, trying to displace Alkermes

Alkermes breaks new ground in narcolepsy with orexin drug

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

sleep disorders

Editor's Picks